Videos

“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview.

“At 34, I have another chance to live the rest of my life with a consciousness that there's great purpose in the pain.”

“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”

“There's a lot of miscommunication and number one, I would tell them you don't need to face these decisions alone,” Dr. Pat Basu said in an interview addressing patient’s fear in the midst of the COVID-19 pandemic.

The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.

An expert explains the importance of the fourth approval of the immunotherapy Tecentriq for certain patients with metastatic non-small cell lung cancer who have a high PD-L1 expression.

“We don't know what the best treatment paradigm is for a patient whose disease is most clearly manifest on a PSMA scan as opposed to standard imaging,” said Dr. Michael J. Morris. “All that work has yet to be done, and we can only do it once we have the scan available to us as a tool in the United States.”

The impact of the COVID-19 pandemic on the cancer landscape has lead to enormous challenges for patients and professionals alike, but the impact of the pandemic will be felt on cancer care for years to come.

“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE®.

Lidia, who was diagnosed with stage 4 lung cancer in 2016, offers her advice for others who have received a cancer diagnosis.

“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.

There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.

In an interview with CURE®, Dr. Pail Paik of the Memorial Sloan Kettering Cancer Center discusses the FDA approval of Alunbrig for patients with ALK-positive metastatic non-small cell lung cancer.

In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.

“I think until you've been put in a position that I'm in, we sometimes tend to take our lives and time that we have for granted.”

“Everything is perspective. It's how you look at it.”

4 Chronic Lymphocytic Leukemia experts hosted a webinar, in partnership with CURE, addressing the latest and most important topics for patients with CLL.

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.

CURE hosted its third webinar on all the latest topics and trends for patients with lung cancer.

In an interview with CURE, Lutheran Medical Center oncology patient navigator Laurie Hatch explains the best ways for patients with cancer and survivors to restart their exercise routine and the best ways to get moving again and combat side effects from treatment like fatigue.

The phase 3 trial evaluating eprenetapopt plus Vidaza completed enrollment recently, and could lead to a new standard of care with positive results, according to Dr. Guillermo Garcia-Manero.

Dr. Caron A. Jacobson discusses the potential long-term impact of Yescarta for patients with relapsed or refractory indolent non-Hodgkin lymphoma and how it could turn an incurable disease into something curable.

“Survivor: Africa” winner Ethan Zohn details his journey with cancer and discovering that it isn’t a sprint, but a marathon.

Rachel J. Wong, an oncology dietitian from Georgetown Lombardi Comprehensive Cancer Center, has some helpful tips on what patients and survivors can stock their pantry with to avoid stress eating and stay healthy through the pandemic and beyond.

Data presented at the ASCO 2020 Virtual Scientific Program demonstrated that Keytruda was an effective treatment for patients with Hodgkin Lymphoma and side effects were tolerable.